The U.S. Food and Drug Administration granted Fast Track designation for Neuraptive Therapeutics Inc.’s franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve injuries.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2020-05-14 15:48:382020-05-15 11:42:07FDA Grants Fast Track Designation to Neuraptive Therapeutics’ NTX-001 Clinical Development Program for Peripheral Nerve Injuries